Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.

JG Einspahr, DS Alberts, SM Gapstur, RM Bostick… - … , biomarkers & prevention …, 1997 - AACR
Surrogate end-point biomarkers (SEBs) have become widely used in short-term cancer
chemoprevention trials in place of cancer end points. This paper discusses criteria relevant …

Safety aspects of pegylated liposomal doxorubicin in patients with cancer

DS Alberts, DJ Garcia - Drugs, 1997 - Springer
Encapsulation in polyethylene glycol-coated (pegylated; Stealth®) liposomes alters the
pharmacokinetic characteristics, and hence the safety and tolerability profile, of doxorubicin …

Factors associated with osteonecrosis of the jaw among bisphosphonate users

LM Hess, JM Jeter, M Benham-Hutchins… - The American journal of …, 2008 - Elsevier
BACKGROUND: Bisphosphonates are medications that impact bone reformation by
inhibiting osteoclast function. Osteonecrosis of the jaw has been reported among patients …

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage …

WA Peters III, PY Liu, RJ Barrett, RJ Stock… - Obstetrical & …, 2000 - journals.lww.com
This study investigated the addition of cisplatin-based chemotherapy to standard
postoperative radiation therapy in the treatment of women at high risk of recurrence after …

[HTML][HTML] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

DS Alberts, PY Liu, EV Hannigan… - … England Journal of …, 1996 - Mass Medical Soc
Background Intravenous platinum-based chemotherapy is the standard primary therapy for
advanced ovarian cancer. We conducted a phase 3 trial to compare the effects of …

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal …

M Markman, BN Bundy, DS Alberts… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: To compare the progression-free and overall survival in small-volume residual
ovarian cancer after treatment with intravenous (IV) cisplatin and paclitaxel or an …

[HTML][HTML] Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas

DS Alberts, ME Martínez, DJ Roe… - … England Journal of …, 2000 - Mass Medical Soc
Background The risks of colorectal cancer and adenoma, the precursor lesion, are believed
to be influenced by dietary factors. Epidemiologic evidence that cereal fiber protects against …

Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4

GR Pettit, SB Singh, E Hamel, CM Lin, DS Alberts… - Experientia, 1989 - Springer
Summary The African tree Combretum caffrum (Combretaceae) has been found to contain a
powerful inhibitor of tubulin polymerization (IC 50 2–3 μM), the growth of murine lymphocytic …

Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs

SE Salmon, AW Hamburger, B Soehnlen… - … England Journal of …, 1978 - Mass Medical Soc
With a direct in vitro tumor-colony assay developed to measure sensitivity of human-tumor
stem cells to anticancer drugs, we performed 32 retrospective or prospective clinical studies …

A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy

ME Martínez, JA Baron, DA Lieberman, A Schatzkin… - Gastroenterology, 2009 - Elsevier
BACKGROUND & AIMS: Limited data exist regarding the actual risk of developing advanced
adenomas and cancer after polypectomy or the factors that determine risk. METHODS: We …